New Drugs: Opdualag
A Dual Immunotherapy for Metastatic Melanoma By Ted Rosen, MD Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab to treat adult and pediatric patients with unresectable or metastatic melanoma. The FDA recently approved a dual immunotherapy drug for the treatment of adult and pediatric patients […]